MovDisordV3, Main, Exploration, bibRecord, 004F32

Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop

Identifieur interne : 004F32 ( Main/Exploration ); précédent : 004F31; suivant : 004F33

Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop

Auteurs : Stanley Fahn [États-Unis] ; Kathleen E. Clarence-Smith [États-Unis] ; Thomas N. Chase [États-Unis]

Source :

Movement Disorders [ 0885-3185 ] ; 1998-09.

RBID : ISTEX:29303C711A531221E5ACF9E60A9720B0CAA82F79

English descriptors

KwdEn :
- Humans, Nerve Degeneration (drug therapy), Nerve Degeneration (physiopathology), Neurons (drug effects), Neurons (physiology), Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Research, Substantia Nigra (drug effects), Substantia Nigra (physiopathology).
MESH :
- chemical , adverse effects : Neuroprotective Agents.
- drug effects : Neurons, Receptors, Dopamine, Substantia Nigra.
- drug therapy : Nerve Degeneration, Parkinson Disease.
- physiology : Neurons, Receptors, Dopamine.
- physiopathology : Nerve Degeneration, Parkinson Disease, Substantia Nigra.
- chemical , therapeutic use : Neuroprotective Agents.
- Humans, Research.

Url:

https://api.istex.fr/document/29303C711A531221E5ACF9E60A9720B0CAA82F79/fulltext/pdf

DOI: 10.1002/mds.870130502

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop</title>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
</author>
<author><name sortKey="Clarence Mith, Kathleen E" sort="Clarence Mith, Kathleen E" uniqKey="Clarence Mith K" first="Kathleen E." last="Clarence-Smith">Kathleen E. Clarence-Smith</name>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:29303C711A531221E5ACF9E60A9720B0CAA82F79</idno>
<date when="1998" year="1998">1998</date>
<idno type="doi">10.1002/mds.870130502</idno>
<idno type="url">https://api.istex.fr/document/29303C711A531221E5ACF9E60A9720B0CAA82F79/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002464</idno>
<idno type="wicri:Area/Istex/Curation">002464</idno>
<idno type="wicri:Area/Istex/Checkpoint">003667</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Fahn S:parkinson:s:disease</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:9756143</idno>
<idno type="wicri:Area/PubMed/Corpus">004359</idno>
<idno type="wicri:Area/PubMed/Curation">004359</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004369</idno>
<idno type="wicri:Area/Ncbi/Merge">005024</idno>
<idno type="wicri:Area/Ncbi/Curation">005024</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005024</idno>
<idno type="wicri:doubleKey">0885-3185:1998:Fahn S:parkinson:s:disease</idno>
<idno type="wicri:Area/Main/Merge">007E44</idno>
<idno type="wicri:Area/Main/Curation">004F32</idno>
<idno type="wicri:Area/Main/Exploration">004F32</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop</title>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>The Neurological Institute, Columbia University, New York, NY</wicri:regionArea>
<placeName><region type="state">État de New York</region>
<settlement type="city">New York</settlement>
</placeName>
<orgName type="university">Université Columbia</orgName>
</affiliation>
</author>
<author><name sortKey="Clarence Mith, Kathleen E" sort="Clarence Mith, Kathleen E" uniqKey="Clarence Mith K" first="Kathleen E." last="Clarence-Smith">Kathleen E. Clarence-Smith</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Prestwick Scientific Capital, Washington, DC</wicri:regionArea>
<placeName><region type="state">District de Columbia</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1998-09">1998-09</date>
<biblScope unit="vol">13</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="759">759</biblScope>
<biblScope unit="page" to="767">767</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">29303C711A531221E5ACF9E60A9720B0CAA82F79</idno>
<idno type="DOI">10.1002/mds.870130502</idno>
<idno type="ArticleID">MDS870130502</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans</term>
<term>Nerve Degeneration (drug therapy)</term>
<term>Nerve Degeneration (physiopathology)</term>
<term>Neurons (drug effects)</term>
<term>Neurons (physiology)</term>
<term>Neuroprotective Agents (adverse effects)</term>
<term>Neuroprotective Agents (therapeutic use)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (physiology)</term>
<term>Research</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (physiopathology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurons</term>
<term>Receptors, Dopamine</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Neurons</term>
<term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Nerve Degeneration</term>
<term>Parkinson Disease</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Research</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>District de Columbia</li>
<li>Maryland</li>
<li>État de New York</li>
</region>
<settlement><li>New York</li>
</settlement>
<orgName><li>Université Columbia</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="État de New York"><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
</region>
<name sortKey="Chase, Thomas N" sort="Chase, Thomas N" uniqKey="Chase T" first="Thomas N." last="Chase">Thomas N. Chase</name>
<name sortKey="Clarence Mith, Kathleen E" sort="Clarence Mith, Kathleen E" uniqKey="Clarence Mith K" first="Kathleen E." last="Clarence-Smith">Kathleen E. Clarence-Smith</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004F32 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004F32 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:29303C711A531221E5ACF9E60A9720B0CAA82F79
   |texte=   Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop

Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions—report of a workshop

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.